{Reference Type}: Journal Article
{Title}: Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Japanese Patients With Venous Thromboembolism　- The Primary Results From the KUROSIO Study.
{Author}: Yamada N;Tamaru S;Umetsu M;Tsujita K;Nakamura M;Watanabe A;Yuzaki M;Nishimura Y;Ogura T;Yamamoto T;Satokawa H;Obayashi T;Nakamura M; ;
{Journal}: Circ J
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 28
{Factor}: 3.35
{DOI}: 10.1253/circj.CJ-23-0954
{Abstract}: <B>BACKGROUND: </B>Direct oral anticoagulants (DOACs) are recommended as the first-choice anticoagulation therapy in the acute phase of venous thromboembolism (VTE). However, there is limited real-world data for Japanese VTE patients.Methods and Results: The KUROSIO study (UMIN000023747) was a prospective long-term observational study comprising 1,017 patients with concurrent acute symptomatic pulmonary thromboembolism and proximal deep vein thrombosis (DVT) or isolated calf DVT initially treated with DOACs. After excluding 24 patients, 993 (mean age, 66.3±15.1 years; 58.6% females) were analyzed. The incidences of recurrent symptomatic VTE and major bleeding for up to 52 weeks after diagnosis were 3.2% and 2.2%, respectively. Multivariate analyses revealed chemotherapy and anemia as significant risk factors associated with recurrent symptomatic VTE and major bleeding, respectively.<BR><B>CONCLUSIONS: </B>The efficacy and safety of DOACs in Japanese patients with VTE were determined in this real-world observational study.